#NewAseBioMember | "AseBio is a strong association of public and private organizations involved in biotech sector development""
Meet BioClonal, our new member. We talked to its with Paula Garfella Founder & CEO and Jessika Valero, CRO.
AseBio. What does your company's work bring to the table and what is its strength?
Paula Garfella y Jessika Valero. BioClonal is a novel biotech company dedicated to the in vivo Rational Antibody Discovery. We develop monoclonal antibodies for use in human therapy, which devises an in vivo technology platform of our creation: RedMabs.
The main contribution that BioClonal makes to the ecosystem is to break the technological barriers around immunization. Using our own adjuvants and immunomodulators, and our specially designed protocols for each target, we can obtain results against targets that until now have been unattainable.
AseBio. What is AseBio for you?
Paula Garfella y Jessika Valero. Is a strong association of public and private organizations involved in biotech sector development.
AseBio. When did you first hear about AseBio?
Paula Garfella y Jessika Valero. In the AseBio investors day.
AseBio. What do you expect from being part of an association like AseBio?
Paula Garfella y Jessika Valero. Being part, increase our networking and apport value to the Spanish biotech ecosystem.
AseBio. What is the biggest challenge facing the biotech sector (or your company)?
Paula Garfella y Jessika Valero. We want to be able to convince we are a key player and partner for the big biotech companies, which we need to continue the project and ensure that the drug we design is accessible to the patients.